Publications by authors named "G Des-Guetz"
Article Synopsis
- A tyrosine-kinase inhibitor (TKI) is recommended as the primary treatment for non-small-cell lung cancer (NSCLC) patients with an epidermal growth-factor receptor mutation, and the effectiveness of combining it with chemotherapy (ChT) is being researched.
- A meta-analysis of four phase III trials involving 1,413 NSCLC patients indicated that the combination of EGFR-TKI and ChT resulted in significantly longer progression-free survival (PFS) and overall survival (OS) compared to EGFR-TKI alone.
- The combination treatment showed especially improved PFS for patients with brain metastases, but more research is necessary to determine which patients are most likely to benefit from this combined approach.
About 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While metastasectomy is known to improve overall and progression-free survival in mCRC, specific results in selected patients with dMMR/MSI mCRC are lacking. Our study aimed to describe metastasectomy results, characterize histological response and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC.
View Article and Find Full Text PDFE-cadherin, a gene product, is a calcium-dependent cell-cell adhesion molecule playing a critical role in the establishment of epithelial architecture, maintenance of cell polarity, and differentiation. Germline pathogenic variants in the gene are associated with hereditary diffuse gastric cancer (HDGC), and large rearrangements in the gene are now being reported as well. Because pathogenic variants could be associated with breast cancer (BC) susceptibility, rearrangements could also impact it.
View Article and Find Full Text PDFBackground: Neoadjuvant fluoropyrimidine (5FU or capecitabine)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still unclear.
Methods: To identify clinical trials combining oxaliplatin in preoperative CRT or perioperative chemotherapy for LARC published until March 2021, we searched PubMed and the Cochrane Library.
Article Synopsis
- Platin-based chemotherapy has historically been the standard treatment for extensive-stage small-cell lung cancer (ES-SCLC), with recent interest in combining it with immune checkpoint inhibitors (ICI+CT) for potential benefits, although results are mixed.
- A meta-analysis of randomized trials involving 2,775 patients showed that ICI+CT significantly improved overall survival and progression-free survival compared to chemotherapy alone, particularly with anti-PD-L1 and anti-PD-1 treatments, but not with anti-CTLA-4.
- Despite the benefits, ICI+CT was associated with more serious adverse events, and patients with brain metastases at diagnosis did not experience better outcomes from ICI+CT compared to standard chemotherapy.